CNO Financial Group, Inc. (CNO) stock intrinsic value fair value estimate & owner earnings analysis

CNO Financial Group is the holding company for Bankers Life, Washington National and Colonial Penn. It sells annuities, Medicare supplement, supplemental health (cancer, heart/stroke, accident), long-term care and life insurance to middle-income and retirement-age Americans, through about 4,600 producing career agents at Bankers Life, a worksite sales force, independent agents and direct-to-consumer marketing. In 2025 it collected about $4.6 billion of premiums. Annuities made up the largest share, followed by life insurance at 21%, supplemental health at 16%, Medicare supplement at 14% and long-term care at 6%. It earns money in two ways: an underwriting margin on its health and life policies, and a spread between what its large bond-heavy investment portfolio earns and what it credits to annuity customers. How we measured earnings. For an insurer, reported operating cash flow badly overstates what belongs to shareholders. The interest CNO credits to annuity customers' accounts ($534 million in 2025) and the build-up of policy reserves are real obligations to policyholders. They are counted as operating cash only because the money leaves later, through withdrawals shown as financing. We measure owner earnings instead as accounting net income with the non-cash, mark-to-market swings removed: fair-value changes on investments, hedge options and annuity guarantees, plus one-time non-cash write-offs such as the $102 million goodwill and asset impairment in 2025, the $704 million loss on ceding the old long-term care block in 2018, and tax-asset revaluations. Realized investment losses from credit impairments and sales are kept in as a genuine cost of running a bond portfolio. On this basis CNO earned about $308 million in 2023, $386 million in 2024 and $350 million in 2025, and between $268 million and $427 million in every year since 2016. What changed since our previous estimate. We previously valued the shares at about $91.50 in the middle case. That estimate treated the annuity interest credits and reserve growth as owner cash, which put earnings near $6.51 per share against roughly $3.50 on the basis above. It also added share-count shrinkage from buybacks as growth, on top of already counting the cash spent on those buybacks. Buybacks at a fair price move value between shareholders; they don't create it. Correcting both lowers every case substantially. On debt, nothing is deducted twice. For an insurer, borrowing (Federal Home Loan Bank advances and funding agreements that fund matched investments) is raw material of the spread business, and its interest is already an operating cost. The holding company's own $1.35 billion of notes also has its interest already deducted in the earnings above. What we have added is the cost of refinancing: $500 million of 5.25% notes due May 2029, alongside $700 million of 6.45% notes due 2034 and $150 million of 5.125% debentures due 2060. Holding-company interest of about $79 million a year is covered many times over in every case. Starting point. We use the median of the five years 2021-2025, about $350 million. That is the period since the current insurance accounting took effect and after the 2018 long-term care reinsurance reshaped the company, and it spans both the low-rate years (2021-2022) and the high-rate years (2023-2025). Spread over today's roughly 95 million diluted shares, that is about $3.69 per share. In 2025 owner earnings fell about 9% from 2024 (about 2% per share). Our middle case still starts with 4% growth in the first year, for a specific reason: in the first half of 2026 pre-tax operating earnings were $281 million against $217 million a year earlier, net income was $164 million against $113 million, and premiums rose 4%. Both quarters were up, not just one. Middle case, about $59.62 per share. Earnings grow 4% in year one and 2% a year through year ten. That is below the roughly 3% a year the business has compounded since 2016, and it rests on the agent-sales engine CNO has run for decades and funds itself: steady gains in Medicare supplement, long-term care and supplemental health premiums, plus annuity sales. After year ten, earnings hold level through year thirty. The long-established distribution franchise has produced $268-427 million of owner earnings in every year since 2016, through 2020 and the 2022 rate shock, but we credit nothing beyond thirty years. We also charge a modest refinancing cost on the 2029 notes. The business is worth about $5.66 billion after all interest. Holding-company notes of $1.35 billion are already carried through that interest, so shareholders' value is the same $5.66 billion. Low case, about $34.95 per share. Earnings drop to about $305 million, the 2022-2023 level. That is what happens if short-term rates fall and the spread income from its Federal Home Loan Bank and funding-agreement programs shrinks: investment income not assigned to product lines rose from $336 million in 2023 to $507 million in 2025, largely on rates. Earnings then stay flat for ten years, with Medicare supplement morbidity continuing to run above assumptions as it has in each of the last three annual reviews. In year two a credit downturn costs about $53 million before tax, as the allowance increase did in 2022. The 2029 notes are refinanced near 7%. After year ten, earnings shrink 5% a year as the book runs off without full replacement, and we stop counting at year twenty-five. The business is worth about $3.32 billion after interest. Against the same $1.35 billion of notes, already carried through the interest charge, shareholders keep about $3.32 billion. High case, about $73.10 per share. The first-half 2026 strength carries into 8% growth in year one, the premium growth already visible continues at 3% a year to year ten, and the franchise holds its earnings level for a further thirty years. The business is worth about $6.94 billion after interest, with the notes again already carried through the interest charge. What could make this wrong: long-term care rate increases need state approval; a deep credit cycle could hit a portfolio heavy in corporate bonds and structured securities; and a sustained drop in annuity sales or surrender spikes would shrink the spread business. On the other side, the recent jump in earnings may prove more lasting than we assume, since we have not raised the starting level on only two quarters. The margin-of-safety price is around $37. That is just above the low case, which leaves a wide margin against an insurer whose results depend on interest rates, credit markets and regulators' approval of rate filings.